Dong-A ST files IND for gastric and pancreatic cancer ADC candidate DA-3501 (Chosun Biz) - Jun 24, 2025 - "Dong-A ST announced on the 24th that its antibody-drug conjugate (ADC) subsidiary, Aptis, has filed an Investigational New Drug (IND) application to enter domestic Phase 1 clinical trials for the ADC candidate ‘DA-3501 (AT-211).' The two companies plan to develop DA-3501 as a treatment for high-difficulty solid tumors such as gastric and pancreatic cancers."
IND • New P1 trial • Gastric Cancer • Pancreatic Cancer
|